CAR-T therapy is available in China through products approved by the National Medical Products Administration (NMPA) and through registered clinical trials, delivered at selected hematology and oncology centers. International patients can be considered, but eligibility is always decided by the treating hospital after a full review of the medical records.
This guide explains the routes, the process and the cost factors. It is general information, not medical advice. Horcare only helps patients access approved products or registered clinical trials, never unregulated cell therapies.
What CAR-T therapy is
CAR-T (chimeric antigen receptor T-cell) therapy is a form of immunotherapy. A patient's own T cells are collected, genetically modified in a laboratory to recognize a target on cancer cells, expanded, and infused back into the patient. Approved uses are mainly in certain blood cancers, such as some relapsed or refractory lymphomas, leukemias and multiple myeloma.
Approved products and clinical trials
There are two legitimate routes in China. The first is an NMPA-approved commercial product, used for its approved indications at qualified centers. The second is a clinical trial that is registered with the appropriate registries and approved by the hospital's ethics committee. Trials have strict inclusion criteria and not every patient will qualify.
Be cautious of any offer that is neither an approved product nor a registered trial, or that promises results. Ask for the product name or trial registration number and check it.
Who decides eligibility
The treating hospital's hematology or oncology team decides eligibility. They typically consider the diagnosis and its subtype, prior treatment lines, current disease status, organ function and overall fitness. Horcare's role is to make sure complete records reach the right team and to relay their questions and decision clearly.
The process and length of stay
- Records review by the hospital and, if appropriate, an in-person evaluation.
- Collection of the patient's T cells (apheresis).
- Manufacturing of the CAR-T cells, during which bridging treatment may be given.
- Conditioning chemotherapy followed by infusion of the cells.
- A monitoring period close to the hospital, because side effects can occur in the weeks after infusion.
In practice, patients and a caregiver should plan for a stay measured in weeks to months rather than days. The hospital will give its own estimate.
What drives the cost
The product or trial route is the biggest factor. Published research has reported that the official list prices of CAR-T products approved in China were around RMB 0.999–1.29 million per infusion at the time of study (Zheng et al., 2024). Trials may cover some costs, but not necessarily hospitalization, tests or travel. Additional costs include evaluation, hospital stay, supportive care and accommodation for the monitoring period.
Horcare publishes no prices. The hospital provides its own estimate after reviewing the case; Horcare's fee is quoted separately in writing. See how payment works.
Next steps
If you are exploring CAR-T, gather pathology, the treatment history with dates, recent imaging and lab results, then request a free case review. You can also read about CAR-T therapy in China and the hospitals that deliver it.
